Chemistry:Fosopamine

From HandWiki

Fosopamine (INN; developmental code names SIM-2055, Z-2055; also known as fosfenamine or N-methyldopamine 4-O-phosphate) is a dopamine receptor agonist of the phenethylamine and catecholamine families which was under development for the treatment of hypertension but was never marketed.[1][2] It is taken orally.[1] Fosopamine is a prodrug of epinine (N-methyldopaine) and is said to be selectively metabolized into epinine in the kidneys.[3] The drug was being developed by AstraZeneca and Zambon Group SpA.[1] It reached phase 2 clinical trials prior to the discontinuation of its development.[1]

See also

  • Neurotransmitter prodrug

References